Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
ZyVersa Therapeutics, Inc. entered into Securities Purchase Agreement with purchasers identified on the signature pages valued at 400,000 shares of common stock, pre-funded warrants for 3,600,000 shares, Series A common warrants f (effective 2023-12-06).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- purchasers identified on the signature pages
- Value
- 400,000 shares of common stock, pre-funded warrants for 3,600,000 shares, Series A common warrants f
- Effective
- 2023-12-06
Exact text from the filing
On December 6, 2023, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement with each purchaser identified on the signature pages thereto (the “Purchase Agreement”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), (i) 400,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 3,600,000 pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of 3,600,000 shares of Common Stock, (iii) 4,000,000 Series A common warrants (the “Series A Common Warrants”) exercisable for an aggregate of 4,000,000 shares of Common Stock, and (iv) 4,000,000 Series B common warrants (the “Series B Common Warrants,” and together with the Series A Common Warrants, the “Common Warrants”) exercisable for an aggregate of 4,000,000 shares of Common Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
ZyVersa Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to 6.0% of gross proceeds, expense reimbursement up to $80,000, non-accountable expen (effective 2023-12-06).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- A.G.P./Alliance Global Partners
- Value
- cash fee equal to 6.0% of gross proceeds, expense reimbursement up to $80,000, non-accountable expen
- Effective
- 2023-12-06
Exact text from the filing
On December 6, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. agreed to act as exclusive placement agent for the issuance and sale of the Shares and Warrants.
View on SEC.gov